Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Recs

0
Player Avatar mdriver78 (63.61) Submitted: 1/3/2013 9:23:29 AM : Underperform Start Price: $2.68 KERX Score: -77.76

Congress added language to delay by two years the implementation of oral-only end-stage renal disease (ESRD) related drugs, including phosphate binders, in the bundled ESRD prospective payment system, until January 1, 2016. Affecting medicare coverage of the drug use.

Featured Broker Partners


Advertisement